Sumatriptan Tablet
Product Images NDC 85766-093

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 85766-093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3 (Label 100mg)

Multiple packaging labels for Sumatriptan Tablets USP 100 mg in oral tablet form by Sportpharm LLC. Labels indicate various quantities including 10, 20, 30, 36, 60, and 90 tablets. Distributed by Aurobindo Pharma USA, Inc., the label features product details, NDC codes, QR codes, and repackaging information.*

FDA Label Image

25 (Label 25mg)

Labels for Sumatriptan Tablets USP 25 mg repackaged and relabeled by Sportpharm LLC. Each label displays the proprietary and generic name, strength (25 mg), NDC codes, quantity (ranging from 9 to 90 tablets), distributor Aurobindo Pharma USA, Inc., and description of the tablets as white to off-white, round, biconvex/debossed. Each label includes lot, expiration date placeholders, drug status RX, and storage instructions.*

FDA Label Image

50 (Label 50mg)

This image displays multiple repackaged and relabeled packaging labels for Sumatriptan Tablets USP 50 mg by Sportpharm LLC. Each label includes the NDC, quantity (ranging from 9 to 90 tablets), distributor Aurobindo Pharma USA, Inc., description of the tablets as white to off-white capsule shaped and biconvex/debossed, batch and expiration fields, and drug status as Rx. The labels also feature barcodes and QR codes and caution statements about federal law and storage.*

FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Line graph showing estimated probability of response over time in minutes from initial dose for Sumatriptan tablets at doses of 25 mg, 50 mg, 100 mg, and placebo. The graph illustrates an increasing response probability with higher doses and longer time post-dose up to 240 minutes.*

FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Poo (Sumatriptan Fig2)

A graph showing estimated probability of remediation or rescue over time in hours from the initial dose for Sumatriptan tablets. The graph compares placebo with Sumatriptan doses of 25 mg, 50 mg, and 100 mg, illustrating increasing efficacy with higher doses across a 24-hour period.*

FDA Label Image

Chemical Structure (Sumatriptan Str)

Chemical structure of Sumatriptan Succinate, showing the molecular arrangement of atoms in the active ingredient used in Sumatriptan tablets by Sportpharm LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.